Veronique Blanchard-Bregeon

Title: Veronique Blanchard-Bregeon: Innovator in Alzheimer's Disease Research

Introduction

Veronique Blanchard-Bregeon is a prominent inventor based in Paris, France. She has made significant contributions to the field of neurodegenerative diseases, particularly Alzheimer's disease. With a total of 2 patents, her work focuses on innovative therapeutic approaches.

Latest Patents

Her latest patents include a groundbreaking H3 receptor antagonist for use in the treatment of Alzheimer's disease. This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease-modifying therapy for Alzheimer's disease, other tauopathies, and related neurodegenerative diseases. Another notable patent involves antibodies specific to the β-amyloid peptides and their uses as diagnostic agents or drugs. This patent describes a monoclonal antibody that specifically binds to the N-terminal region of the Aβ peptide, demonstrating high affinity and specificity.

Career Highlights

Throughout her career, Veronique has worked with leading companies in the pharmaceutical industry, including Sanofi and Innogenetics N.V. Her expertise and innovative approaches have positioned her as a key figure in the development of treatments for Alzheimer's disease.

Collaborations

Veronique has collaborated with notable professionals in her field, including Eugeen Vanmechelen and Pierre Grognet. These partnerships have further enhanced her research and contributions to the scientific community.

Conclusion

Veronique Blanchard-Bregeon is a trailblazer in Alzheimer's disease research, with a focus on innovative therapies and diagnostic tools. Her patents and collaborations reflect her commitment to advancing the understanding and treatment of neurodegenerative diseases.